1. Bull, Bear & Beyond – The Biotech Growth Trust in 60 seconds

"Edison’s investment companies team recently published a review of The Biotech Growth Trust (BIOG). The trust’s managers Geoff Hsu and Josh Golomb at leading global healthcare specialist OrbiMed are positive on the outlook for biotech stocks. Higher interest rates have pressured the sector’s valuation despite a favourable fundamental industry backdrop, which includes a high level of innovation, elevated new drug approvals and robust merger and acquisition activity ahead of a major patent cliff. BIOG has a structural bias towards smaller-cap biotech companies, which has been beneficial over the long term but detrimental during the recent industry sell off. The managers are expecting history to repeat, with small-cap biotech stocks leading an industry recovery, which may be amplified by a reduction in US interest rates.

**************************************************************************************

About ‘Bull, Bear & Beyond’

Bull, Bear & Beyond': features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

 About Edison:

Edison is a content-led IR business. We believe quality investment content should inform all investors, not just brokers. Our mission: engage and build bigger, better-informed investor audiences for our clients.

Edison covers 50+ investment trusts, read about them here: https://www.edisongroup.com/equities/investment-companies/

Original interview published on 03/09/2024 and reposted as a podcast"